Premium
High dose chemotherapy including paclitaxel (T‐ICE) combined with peripheral blood stem cell transplantation for male germ cell tumor. Preliminary report
Author(s) -
HARA ISAO,
YAMADA YUJI,
KUMANO MASAFUMI,
FURUKAWA JUNYA,
YAMANAKA KAZUKI,
FUJISAWA MASATO
Publication year - 2005
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2005.01235.x
Subject(s) - medicine , etoposide , chemotherapy , carboplatin , ifosfamide , paclitaxel , urology , lymph node , oncology , surgery , gastroenterology , cisplatin
Aim: To evaluate the feasibility and usefulness of high dose chemotherapy including paclitaxel (T‐ICE) combined with peripheral blood stem cell transplantation (PBSCT) for male germ cell tumor. Methods: Five male patients with advanced germ cell tumor underwent 1–6 courses of high dose chemotherapy including paclitaxel (T‐ICE; 175 mg/m 2 of paclitaxel, 1250 mg/m 2 of carboplatin, 1500 mg/m 2 of etoposide and 7.5 g/m 2 of ifosfamide) with PBSCT after 2–3 courses of induction chemotherapy (PEB or VIP). Results: In all patients, serum marker levels decreased to within the normal range by T‐ICE. Two patients underwent resection of residual tumor. In one patient, viable cancer cells were detected in resected lymph node tissue and adjuvant chemotherapy was then performed. Although the follow‐up period was short (7–15.5 months), four of the five patients (80%) showed no evidence of recurrent disease. No significant differences in side‐effects were noted between T‐ICE and conventional high dose ICE, which was previously performed in 39 patients at the Division of Urology, Kobe University Graduate School of Medicine, Japan. Conclusions: High dose chemotherapy, including T‐ICE, combined with PBSCT showed an almost identical degree of side‐effects as seen in previous high dose chemotherapy without paclitaxel. Although 80% of the patients showed no evidence of disease so far, the efficacy of T‐ICE should be evaluated with more patients and longer follow up.